-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Danavorexton in Idiopathic Hypersomnia (IH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Danavorexton in Idiopathic Hypersomnia (IH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Danavorexton in Idiopathic Hypersomnia (IH) Drug Details: Danavorexton is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – DSP-0187 in Idiopathic Hypersomnia (IH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DSP-0187 in Idiopathic Hypersomnia (IH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DSP-0187 in Idiopathic Hypersomnia (IH) Drug Details: DSP-0187 is under development...
-
Sector Analysis
NewMiddle East and Africa (MEA) Fibercos and Towercos Market Dynamics and Opportunities
Middle East and Africa Fibercos and Towercos Market Report Overview Many countries in the Middle East and Africa (MEA) are focusing on expanding connectivity, building network infrastructure, and attracting subscribers. In 2023, mobile subscription penetration in MEA stood at more than 66% of the population. The MEA Fibercos and Towercos market research report provides an executive-level overview of the drivers and trends that are shaping the market. The report also gives an overview of the latest developments in the fiberco...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Pitolisant Hydrochloride in Idiopathic Hypersomnia (IH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pitolisant Hydrochloride in Idiopathic Hypersomnia (IH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pitolisant Hydrochloride in Idiopathic Hypersomnia (IH) Drug Details: Pitolisant hydrochloride...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALKS-2680 in Idiopathic Hypersomnia (IH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALKS-2680 in Idiopathic Hypersomnia (IH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALKS-2680 in Idiopathic Hypersomnia (IH) Drug Details: ALKS-2680 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Mazindol ER in Idiopathic Hypersomnia (IH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mazindol ER in Idiopathic Hypersomnia (IH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mazindol ER in Idiopathic Hypersomnia (IH) Drug Details: Mazindol ER...
-
Company Insights
Innovation and Patenting activity of IHS Markit Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of IHS Markit Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Golexanolone in Idiopathic Hypersomnia (IH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Golexanolone in Idiopathic Hypersomnia (IH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Golexanolone in Idiopathic Hypersomnia (IH) Drug Details: Golexanolone (GR-3027) (CVXL-0060) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Pentylenetetrazol in Idiopathic Hypersomnia (IH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pentylenetetrazol in Idiopathic Hypersomnia (IH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pentylenetetrazol in Idiopathic Hypersomnia (IH) Drug Details: Pentylenetetrazol (PTZ) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KP-1077 in Idiopathic Hypersomnia (IH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KP-1077 in Idiopathic Hypersomnia (IH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KP-1077 in Idiopathic Hypersomnia (IH) Drug Details: KP-1077 is under development...